Ginsenoside Rc:A potential intervention agent for metabolic syndrome
10.1016/j.jpha.2023.08.013
- Author:
Zhengjie LU
1
,
2
,
3
;
Tongyun MAO
;
Kaiqi CHEN
;
Longxin CHAI
;
Yongguo DAI
;
Kexin LIU
Author Information
1. Department of Pharmacy,Zhongnan Hospital of Wuhan University,Wuhan,430072,China
2. Department of Orthopedic Surgery,Zhongnan Hospital of Wuhan University,Wuhan,430072,China
3. Department of Pharmacology,Wuhan University School of Basic Medical Sciences,Wuhan,430071,China
- Keywords:
Ginsenoside Rc;
Metabolic syndrome;
Obesity;
Diabetes;
Atherosclerosis
- From:
Journal of Pharmaceutical Analysis
2023;13(12):1375-1387
- CountryChina
- Language:Chinese
-
Abstract:
Ginsenoside Rc,a dammarane-type tetracyclic triterpenoid saponin primarily derived from Panax ginseng,has garnered significant attention due to its diverse pharmacological properties.This review outlined the sources,putative biosynthetic pathways,extraction,and quantification techniques,as well as the pharmacokinetic properties of ginsenoside Rc.Furthermore,this study explored the pharmaco-logical effects of ginsenoside Rc against metabolic syndrome(MetS)across various phenotypes including obesity,diabetes,atherosclerosis,non-alcoholic fatty liver disease,and osteoarthritis.It also highlighted the impact of ginsenoside Rc on multiple associated signaling molecules.In conclusion,the anti-MetS effect of ginsenoside Rc is characterized by its influence on multiple organs,multiple targets,and multiple ways.Although clinical investigations regarding the effects of ginsenoside Rc on MetS are limited,its proven safety and tolerability suggest its potential as an effective treatment option.
